PAVmed, Inc.

As of October 24, 2025, PAVmed, Inc. is considered overvalued with a valuation grade of fair, reflected by poor financial metrics and significant underperformance against the S&P 500, showing a year-to-date return of -34.92% compared to the index's 15.47%.

As of October 24, 2025, PAVmed, Inc. is considered overvalued with a fair valuation grade, reflected by key metrics such as a Price to Book Value of 0.23 and a year-to-date return of -34.92%, significantly underperforming the S&P 500's 15.47%.

As of September 2, 2025, PAVmed, Inc. shows a mildly bearish trend with mixed indicators, having underperformed the S&P 500 by -74.41% over the past year.

As of September 2, 2025, PAVmed, Inc. has shifted from a fair to an attractive valuation grade, indicating it may be undervalued with metrics like a Price to Book Value of 0.23, despite a significant 98.33% decline in stock performance over the past five years compared to a 96.61% increase in the S&P 500.

As of May 15, 2025, PAVmed, Inc. is considered very attractive and undervalued with a price-to-book value of 0.23 and an impressive ROE of 92.94%, despite a lagging stock performance compared to the S&P 500.

As of June 13, 2025, PAVmed, Inc. shows a mildly bearish trend due to bearish daily moving averages and Bollinger Bands, despite some bullish signals in the weekly MACD and monthly indicators, indicating overall cautious sentiment.

As of March 2022, PAVmed, Inc.'s management team includes Lishan Aklog as Chairman and CEO, and Michael Glennon as Independent Vice Chairman, along with independent directors Dr. David Battleman, Dr. James Cox, Mr. Ronald Sparks, and Mr. David Weild.

PAVmed, Inc. is a micro-cap medical device company focused on developing and commercializing a diverse range of products in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $0 million and a net profit of $19 million, with a market cap of $10.58 million.

As of Jun 18, PAVmed, Inc. has a market capitalization of 10.58 million and reported net sales of 2.00 million with a consolidated net profit of 65.56 million. The balance sheet shows shareholder's funds of -2.50 million and total assets of 30.66 million.